MedTrace Logo

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

NCT02210104 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2017-07-21

No results posted yet for this study

Summary

The goal of this clinical research study is to learn about the safety of giving CD4+T cells with ipilimumab and cyclophosphamide.

CD4+T cells are a type of white blood cell. Researchers grow the T cells in the laboratory, and they are designed to find cancer cells and may kill them.

Conditions

Interventions

DRUG

Ipilimumab

Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.

DRUG

Cyclophosphamide

300 mg/m2 administered intravenously 2 days prior to T cell infusion.

BIOLOGICAL

CD4+ T cells

Antigen-specific CD4+ T cells administered at a dose of 10\^10 cells/m\^2 on Day 0.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Cassian Yee, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02210104 on ClinicalTrials.gov